Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma.

Measles virus Edmonston strain (MV-Edm) is thought to have remarkable oncolytic activity that selectively destroys human tumor cells. The P/V/C protein of wild-type MV was shown to resist the antiviral effects of interferon (IFN)-alpha. Here, we engineered new MVs by arming MV-Edm tag strain (a V-defective vaccine-lineage strain, MV-Etag) with the P or N, P, and L genes of wild-type MV (MV-P and MV-NPL, respectively). The oncolytic activities of the MVs were determined in human renal cell carcinoma (RCC) cell lines and primary human RCC cells by the MTT assay. The antitumor efficacy of the MVs was evaluated in A-498 xenografts in nude mice. IFN-alpha effectively inhibited the replication of MV-Etag and MV-P, but not MV-NPL. MV-NPL more efficiently induced cytopathic effects (CPEs) in OS-RC-2 cells, even in the presence of human IFN-alpha. MV-NPL replicated more rapidly than MV-P and MV-Etag in A-498 cells. Apoptosis was induced earlier in A-498 cells by MV-NPL than MV-Etag and MV-P. MV-NPL showed more significant antitumoral effects and had prolonged replication compared to MV-Etag and MV-P. In this study, we demonstrated that the newly engineered MV-NPL has more effective oncolytic activity and may help establish an innovative cancer therapy.

[1]  D. Gerlier,et al.  Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus , 1993, Journal of virology.

[2]  M. Takeda,et al.  Contributions of Matrix and Large Protein Genes of the Measles Virus Edmonston Strain to Growth in Cultured Cells as Revealed by Recombinant Viruses , 2005, Journal of Virology.

[3]  S. Longhi,et al.  [Structural disorder within the replicative complex of measles virus: functional implications]. , 2005, Virologie.

[4]  R. Dummer,et al.  Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. , 2005, Blood.

[5]  W. Zou,et al.  Significant antitumor activity of oncolytic adenovirus expressing human interferon‐β for hepatocellular carcinoma , 2008, The journal of gene medicine.

[6]  V. ter meulen,et al.  Selective in vivo suppression of T lymphocyte responses in experimental measles virus infection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Hiscott,et al.  The interferon antiviral response: from viral invasion to evasion , 2002, Current opinion in infectious diseases.

[8]  D. Nettelbeck,et al.  Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. , 2002, Cancer research.

[9]  M. Takeda,et al.  Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. , 2004, The Journal of general virology.

[10]  M. Billeter,et al.  Rescue of measles viruses from cloned DNA. , 1995, The EMBO journal.

[11]  P. Mishra,et al.  Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. , 2003, Cancer research.

[12]  H. Saito,et al.  Measles virus suppresses interferon-α signaling pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-α receptor complex , 2003 .

[13]  D. Kirn,et al.  Gene therapy progress and prospects cancer: oncolytic viruses , 2008, Gene Therapy.

[14]  D. Kirn,et al.  Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer , 2009, Nature Reviews Cancer.

[15]  M. Coffey,et al.  A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer , 2008, Clinical Cancer Research.

[16]  K. Nagata,et al.  Measles virus V protein blocks interferon (IFN)‐α/β but not IFN‐γ signaling by inhibiting STAT1 and STAT2 phosphorylation , 2003 .

[17]  A. Dispenzieri,et al.  Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. , 2006, Experimental hematology.

[18]  J. Ingle,et al.  A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer , 2006, Breast Cancer Research and Treatment.

[19]  C. Koumenis,et al.  Replication and Cytopathic Effect of Oncolytic Vesicular Stomatitis Virus in Hypoxic Tumor Cells In Vitro and In Vivo , 2004, Journal of Virology.

[20]  S. Russell,et al.  High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus , 2004, Cancer Research.

[21]  F. Tangy,et al.  Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. , 2008, Cancer research.

[22]  Y. Yanagi,et al.  SLAM (CDw150) is a cellular receptor for measles virus , 2000, Nature.

[23]  S. Russell.  RNA viruses as virotherapy agents , 2002, Cancer Gene Therapy.

[24]  L. Dunster,et al.  Pathogenetic aspects of measles virus infections. , 1995, Veterinary microbiology.

[25]  C. Horvath,et al.  STAT2 Is a Primary Target for Measles Virus V Protein-Mediated Alpha/Beta Interferon Signaling Inhibition , 2008, Journal of Virology.

[26]  Zhenghong Yuan,et al.  Measles Virus Infection in Adults Induces Production of IL-10 and Is Associated with Increased CD4+CD25+ Regulatory T Cells1 , 2008, The Journal of Immunology.

[27]  Roberto Cattaneo,et al.  Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded , 2008, Nature Reviews Microbiology.

[28]  S. Russell,et al.  Engineering oncolytic measles virus to circumvent the intracellular innate immune response. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  M. Takeda,et al.  Measles Viruses Possessing the Polymerase Protein Genes of the Edmonston Vaccine Strain Exhibit Attenuated Gene Expression and Growth in Cultured Cells and SLAM Knock-In Mice , 2008, Journal of Virology.

[30]  R. Johnston,et al.  Reovirus and tumor oncolysis. , 2007, Journal of microbiology.

[31]  N. LaRusso,et al.  Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma , 2006, Hepatology.

[32]  R. Martuza,et al.  Oncolytic viral therapies – the clinical experience , 2005, Oncogene.

[33]  L. Hartmann,et al.  Intraperitoneal therapy of ovarian cancer using an engineered measles virus. , 2002, Cancer research.

[34]  A. Kato,et al.  Differential Type I IFN-Inducing Abilities of Wild-Type versus Vaccine Strains of Measles Virus1 , 2007, The Journal of Immunology.

[35]  B. Bodey,et al.  MTH-68/H Oncolytic Viral Treatment in Human High-Grade Gliomas , 2004, Journal of Neuro-Oncology.

[36]  X. Zhang,et al.  An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer , 2007, Cancer Gene Therapy.

[37]  Christopher D. Richardson,et al.  The human CD46 molecule is a receptor for measles virus (Edmonston strain) , 1993, Cell.

[38]  S. Sugano,et al.  Phosphorylation of measles virus nucleoprotein upregulates the transcriptional activity of minigenomic RNA , 2008, Proteomics.

[39]  D. Dingli,et al.  Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. , 2004, Blood.

[40]  R. Friedman,et al.  Evasion of Host Defenses by Measles Virus: Wild-Type Measles Virus Infection Interferes with Induction of Alpha/Beta Interferon Production , 2000, Journal of Virology.

[41]  G. Kochs,et al.  The interferon response circuit: Induction and suppression by pathogenic viruses , 2005, Virology.

[42]  Y. Nagai,et al.  Recovery of Pathogenic Measles Virus from Cloned cDNA , 2000, Journal of Virology.

[43]  G. Ahmann,et al.  Systemic therapy of myeloma xenografts by an attenuated measles virus. , 2001, Blood.

[44]  M. Blixenkrone-Møller,et al.  Measles virus-induced modulation of host-cell gene expression. , 2002, Journal of General Virology.